Affiliation:
1. Department of Physiological Sciences, College of Veterinary, Oklahoma State University, Stillwater, OK 74078, USA
Abstract
Nanoparticles (NPs) have the ability to transform poorly immunogenic tumors into activated ‘hot’ targets. In this study, we investigated the potential of a liposome-based nanoparticle (CRT-NP) expressing calreticulin as an in-situ vaccine to restore sensitivity to anti-CTLA4 immune checkpoint inhibitor (ICI) in CT26 colon tumors. We found that a CRT-NP with a hydrodynamic diameter of approximately 300 nm and a zeta potential of approximately +20 mV induced immunogenic cell death (ICD) in CT-26 cells in a dose-dependent manner. In the mouse model of CT26 xenograft tumors, both CRT-NP and ICI monotherapy caused moderate reductions in tumor growth compared to the untreated control group. However, the combination therapy of CRT-NP and anti-CTLA4 ICI resulted in remarkable suppression of tumor growth rates (>70%) compared to untreated mice. This combination therapy also reshaped the tumor microenvironment (TME), achieving the increased infiltration of antigen-presenting cells (APCs) such as dendritic cells and M1 macrophages, as well as an abundance of T cells expressing granzyme B and a reduction in the population of CD4+ Foxp3 regulatory cells. Our findings indicate that CRT-NPs can effectively reverse immune resistance to anti-CTLA4 ICI therapy in mice, thereby improving the immunotherapeutic outcome in the mouse model.
Funder
National Cancer Institute of the National Institutes of Health
Focused Ultrasound Foundation, PETCO, and the Kerr (Ranjan) Endowed Chair at Oklahoma State University
Reference58 articles.
1. Sato, Y., Fu, Y., Liu, H., Lee, M.Y., and Shaw, M.H. (2021). Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer, 21.
2. Immune microenvironment modulation unmasks thera-peutic benefit of radiotherapy and checkpoint inhibition;Newton;J. Immunother. Cancer,2019
3. Oncology Meets Immunology: The Cancer-Immunity Cycle;Chen;Immunity,2013
4. The hallmarks of successful anticancer immunotherapy;Galluzzi;Sci. Transl. Med.,2018
5. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer;Rech;Nature,2015